Acorda Therapeutics up 7% on patent ruling

• The company has won Patent Office rulings on all four Ampyra (dalfampridine) patents.
• ACOR +7%
• Update: Hedge fund honcho Kyle Bass was the challenger through his Coalition for Affordable Drugs. The USPTO ruled that the information he used to support his petition was not publicly available so it could not be used to invalidate the patents. If he had prevailed, though, there are additional patents protecting Ampyra through 2026.
• The Coalition has filed more than 24 petitions challenging drug patents. Earlier this week, it filed three new ones directed at patents covering Insys Therapeutics' (INSY -1%) pain med Subsys (fentanyl). In about a month, the USPTO's Patent Trial and Appeal Board will decide whether to allow an inter partes review of patents covering two Shire (SHPG +0.1%) drugs, ulcerative colitis med Lialda (mesalamine) and Gattex (teduglutide [rDNA origin]) for short bowel syndrome.